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Background: The focus of Specialized Palliative Care (SPC) is to improve care for patients with incurable diseases
and their families, which includes the opportunity to make their own choice of place of care and ultimately place
of death.
The Danish Palliative Care Trial (DOMUS) aims to investigate whether an accelerated transition process from
oncological treatment to continuing SPC at home for patients with incurable cancer results in more patients
reaching their preferred place of care and death. The SPC in this trial is enriched with a manualized psychological
intervention.
Methods/Design: DOMUS is a controlled randomized clinical trial with a balanced parallel-group randomization
(1:1). The planned sample size is 340 in- and outpatients treated at the Department of Oncology at Copenhagen
University Hospital. Patients are randomly assigned either to: a) standard care plus SPC enriched with a standardized
psychological intervention for patients and caregivers at home or b) standard care alone. Inclusion criteria are
incurable cancer with no or limited antineoplastic treatment options.
Discussion: Programs that facilitate transition from hospital treatment to SPC at home for patients with incurable
cancer can be a powerful tool to improve patients’ quality of life and support family/caregivers during the disease
trajectory. The present study offers a model for achieving optimal delivery of palliative care in the patient’s
preferred place of care and attempt to clarify challenges.
Trial registration: Clinicaltrials.gov Identifier: NCT01885637
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Patient careBackground
The Capital Region of Denmark had in 2013 1,735,521
inhabitants with one of the highest incidences (0.6%)
and prevalence (4.3%) of cancer in the world as well as a
high cancer mortality rate (6.8%). Almost five thousand
of the inhabitants of the Capital Region dies of cancer
every year (0.25%) [1]. Thus, a substantial need for pal-
liative cancer care is observed.* Correspondence: mie.juul.nordly@regionh.dk
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unless otherwise stated.Studies have shown that most patients with advanced
cancer prefer to spend the last part of their life at home
(50-90%) [2,3]. However, in most western countries
more than half of the patients with advanced cancer die
in hospitals [3-9]. A recent systematic review by Gomes
et al. showed that most people with different terminal
diseases preferred to die at home and the majority of
patients did not change preferences as their illnesses
progressed [10]. Similar preferences were reported in a
retrospective Danish survey, which indicated that the
majority of cancer patients in the palliative care phase
preferred to die in their own home (81%); however, the
reported preference for dying at home decreased towardsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Danish study indicated that the majority (71%) of cancer
patients in palliative care preferred to die in their own
home [12]. According to the National Board of Health,
55% of Danish cancer patients died in hospitals, 18% in
nursing homes or in specialist palliative care institu-
tions, while only 26% died at home in 2005 [13]. A simi-
lar pattern is seen in other European countries, as the
place of death in Europe is most frequently hospital or
nursing home [14]. Even in the UK, which has a well-
developed and comprehensive national palliative care
system, a study analyzing all cancer deaths between
1993 and 2010 showed that 48% died in a hospital and
16% in hospices, while 25% died at home [15]. Timely
and continuous involvement of General Practitioners (GP),
nurses and - when necessary - a Specialized Palliative
Care Team (SPT) seems to have a positive impact on
the likelihood of dying at home [16,17]. Experience from
the UK also showed that pronounced delay in the dis-
charge from the hospital was a major obstacle to achieving
the preferred place of palliative care and death [18].
In cancer care the availability of SPC seems to be a
strong predictor for achieving home deaths [19-22]. A
prospective study demonstrated that agreement and un-
derstanding between patients and informal caregivers
about patients’ preferred place of palliative care seems to
be a crucial prerequisite for obtaining death at home
[23]. Grande and Ewing found that this consensus re-
sulted in a substantial likelihood that the patient died at
his or her preferred place [23]. It is interesting to note
that place of death can be a proxy for place of care. A
systematic review from 2006 explored the factors influen-
cing death at home [24]. Among the main factors strongly
associated with death at home, patient’s preference for
home death and home care were clearly expressed [24].
Integration and coordination between oncological treat-
ment, SPC and standard care may be the best way to
organize the palliative care for patients with cancer [25].
This approach could give patients the advantage of timely
access to care at home and simultaneous improvement of
symptom control and quality of life [25]. Brumley et al.
conducted a randomized controlled trial of palliative care
at home with terminally ill patients (late-stage patients
with cancer, chronic obstructive pulmonary disease, and
congestive heart failure), which reported a significant in-
crease in satisfaction with care 30 and 90 days after enroll-
ment [26]. More patients died at home (71%) compared to
those receiving standard care (51%) and the intervention
group was less likely to visit emergency rooms or be ad-
mitted to hospitals (36% compared to 59% in the control
group), resulting in significantly lower costs [26].
Another advantage of SPC at home is the possibility to
support bereaved relatives and caregivers [27]. In most
cases, the grief process is uncomplicated, however, forup to 15% of bereaved relatives grief may develop into a
psycho-pathological condition [28]. The World Health
Organization’s (WHO) definition of palliative care em-
phasizes that the informal caregivers’ health and needs
should also be assessed and supported in palliative care
[29]. Informal caregivers of patients with advanced can-
cer can experience deterioration of their own health and
mental well-being [30]. Furthermore, caregivers’ wishes
regarding the place of death for their loved ones and
their perception of the social support they received seem
to be significantly associated with place of death [31].
We also considered measures of telomere length in
caregivers of cancer patients as a measure for an effect
of the intervention. The pathophysiological consequences
of caregiving have not been fully elucidated and several
studies indicate that caregivers’ stress and strain may be
associated with shorter telomere length, a marker of cellu-
lar aging. A study of 338 caregivers in the 2008–2010 Sur-
vey of the Health of Wisconsin observed significantly
shorter telomere length associated with number of hours
per week of caregiving, caring for a younger individual,
and more strain. Caregivers with discordant levels of stress
and strain (i.e., low perceived stress/high strain) compared
with low stress/low strain had significantly shorter telo-
meres corresponding to approximately 10–15 additional
years of aging [32].
Thus, the DOMUS study protocol will describe an in-
vestigation of accelerated transition from oncological
treatment to SPC at home for patients with incurable
cancer in order to support patients and their informal
caregivers to reach and stay in their preferred place of
care and death.
Study objectives
The primary aim of DOMUS is to investigate whether
an accelerated transition process from oncological treat-
ment to SPC at home for patients with incurable cancer
results in prolonged residence in their preferred place of
care, which indirectly may increase the number of home
deaths. The secondary aims are to investigate whether
the intervention:
– relieves patients’ symptoms (pain, tiredness,
drowsiness, nausea, vomiting, dyspnea, insomnia,
appetite, constipation, and diarrhea)
– improves patients’ and the closest relatives’ quality
of life (health related quality of life)
– relieves patients’ as well as caregivers’ psychosocial
problems (depression, anxiety, dyadic coping, and
caregiver burden)
– ameliorates the bereavement process among the closest
relatives (anxiety, depression, loss- and restoration-
oriented coping, prolonged grief, sleep, lifestyle)
– prolongs survival of patients
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DOMUS is a controlled randomized clinical trial (RCT)
with a balanced parallel-group randomization (1:1). Three-
hundred-and-forty in- and outpatients in the Department
of Oncology, Copenhagen University Hospital, will be
randomly assigned to either an accelerated transition
from oncological treatment to standard care plus
continuing SPC enriched with a manualized psycho-
logical intervention at home (including nursing home) orFigure 1 Description of the content of the intervention and the contrstandard care alone (Figure 1). The transition does not
mean that oncological treatment has to be finalized.
Patient selection
Inclusion and exclusion criteria are demonstrated in List
of Inclusion and exclusion criteria of the DOMUS study:
List of Inclusion and exclusion criteria of the DOMUS study
Inclusion criteria
– Adult (at least 18 year old) cancer patients treated at
the Department of Oncology, Copenhagen University
Hospitalol group.
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possible in their own homes supported by a SPT
– Patients with incurable cancer
– Patients with no or limited antineoplastic treatment
optionsa or patients who resign antineoplastic
treatment
– Patients living in the Capital Region, Denmark
– Written informed consent
a) Limited antineoplastic treatment options are specified
in Table 1.
SPT = specialized palliative care team.Exclusion criteria
– Patients who have already been referred to a SPT
– Hospitalized patients who are not judged capable of
being discharged home
– Patients who are admitted to other hospitals
– Patients who do not speak Danish well enough to
answer the questionnaires
– Patients who are considered incapable of
cooperating in the trialInclusion criteria for caregivers
– Adults (at least 18 years of age)
– Written informed consent (in addition to that from
the patient)
All included patients live in the Capital Region and are
treated at the Department of Oncology, Copenhagen
University Hospital. Limited antineoplastic treatment
options listed in the inclusion criteria are dispelled in
Table 1. A standard procedure is implemented to ensure
that patients with varied diagnosis from the different
clinics are screened evenly. In practice, it means that
inpatients are screened on a daily basis and outpatients








Prostate cancer/Bladder cancer/Penile cancer/Thyme cancer/Adrenal carcinom
Cancer of Unknown Primary origin (CUP)
Head and neck cancerthat guarantees an equal screening frequency of the six
outpatient clinics involved in this study.
Recruitment
Project nurses recruit patients from the oncology wards
and outpatient clinics. From June 2013 to June 2015
three project nurses daily screen in- and outpatients
from the Department of Oncology, Copenhagen Univer-
sity Hospital, and contact selected patients after having
examined medical records to determine whether the pa-
tients are eligible for inclusion in the trial.
Before the patient agrees to participate in DOMUS, an
information meeting will be held, to give the patients
and closest relative oral and written information about
the trial. If the patient gives consent to participate, an in-
formal caregiver, appointed by the patient, is also invited
to participate. Upon consent, the baseline questionnaires
will be completed followed by randomization of the pa-
tient. A blood sample will be taken from the caregiver
within a week to measure the leukocyte telomere length
(a stress level marker).
Randomization
The randomization is computer-generated by a statistician
who is not attached to the project, the allocation sequence
and block size are unknown to the involved nurses, who
recruit patients and collect data. The allocation ratio will
be 1:1. After the patient have given informed consent and
filled out the baseline questionnaire, the nurses draw a
sealed envelope, which is packed by uninvolved staff and
contains information about randomization group.
Intervention group
In the intervention group several steps will take place. A
meeting is held with a research nurse one or two days
after randomization, where the patient (and informal
caregiver) discusses the patient’s wishes for treatment
and care at home and how these can be reconciled with
the caregiver’s wishes. The patient and caregiver’s percep-
tions of challenges and concerns related to home care ares
Limited treatment options
Refractory to 3rd line antineoplastic treatment for metastatic disease
Refractory to 1st line chemotherapy for metastatic/advanced disease
Refractory to 1st line chemotherapy for metastatic/advanced disease
Refractory to 2nd line chemotherapy for metastatic/advanced disease
Refractory to 1st line chemotherapy for metastatic/advanced disease
Refractory to concomitant/adjuvant chemotherapy
as Refractory to 1st line chemotherapy for metastatic/advanced disease
Refractory to 1st line chemotherapy for metastatic/advanced disease
Refractory to radiation therapy or surgery with curative intention
Nordly et al. BMC Palliative Care 2014, 13:44 Page 5 of 10
http://www.biomedcentral.com/1472-684X/13/44explored and addressed. Shortly after the meeting, any ne-
cessary changes regarding the home interior are planned.
Four to five days after randomization a home confer-
ence is held including the patient, caregiver, representa-
tives of the SPT, a district nurse, and if possible the GP
and project psychologist. The SPT, in collaboration with
the GP and the district nurse, is now responsible for the
distribution of tasks related to further treatment and care
(Figure 1).
Only two of nine SPTs in the Capital Region have psy-
chologists to support and treat patients and their relatives
in their homes [33]. Therefore, in order to support pa-
tients and caregivers included in the intervention group, a
standardized psychological intervention along with the
regular SPT intervention (physician and nurse) is added.
Patients and caregivers receive a psychological supportive
care intervention, beginning after the home conference.
The intervention is conducted based on a manual, devel-
oped for the DOMUS trial to describe and standardize the
use of a joint patient-caregiver psychological intervention
in a palliative care setting.
Control group
In the control group, the patients follow current practice
in the healthcare system, being standard care as described
below. If the patient is allocated to the control group, an
additional meeting with the patient and the informal care-
giver will be offered to clarify the options available in case
of unmet palliative needs. A patient allocated to the con-
trol group can obtain equivalent elements of treatment
and care as a patient allocated to the intervention group;
however, the flow and sequence may be different.
Standard care
Patients allocated to both groups will remain patients of
the Department of Oncology at Rigshospitalet and con-
tinue oncological treatment if the oncologist find it rele-
vant. General care provided according to the precepts of
the Danish healthcare system includes in-hospital treat-
ment as well as a GP, a GP out-of-hours service and access
to 24-hour home nursing or nursing homes. Patients and
caregivers may – if needed - receive psychological coun-
seling through referral from their GP. Patients can be re-
ferred to SPC if their GP and/or oncologist judge this to
be relevant. The current practice is referral due to com-
plex palliative care needs.
The Danish healthcare system is financed through taxes
and is free of charge at the point of receipt.
Specialized palliative care
The definition of SPC in Denmark is based on the European
Associations of Palliative Care’ statement [14]: “Specialist
palliative care services require a team approach, combin-
ing a multi-professional team with an interdisciplinarymode of work. Team members must be highly qualified
and should have their main focus of work in palliative
care” [14]. At the moment 18 hospices, four hospital
wards and 28 SPTs fulfill these requirements through-
out the country. In the Capital Region there are nine
SPTs; four of them are hospice-based and five are hospital-
based [33].
Assessments
Project nurses collect baseline data from patient records
regarding the medical history of the included patients.
Patients and caregivers are asked to complete question-
naires (Table 2) before they are randomized and after 2,
4, and 8 weeks and 6 months. Caregivers (bereaved) will
be asked to fill in questionnaires (Table 2) two weeks
and 2, 7, 13 and 19 months after the patient’s death. The
selection of questionnaires was based on previous experi-
ence, validation and availability in the Danish language. As
we do not want to burden the participants it is stated in
each of the questionnaires that patient/caregiver/bereaved
are welcome to fill it in over two days. Each questionnaire
package is estimated to take approximately 30 minutes to
fill in.
In addition, patient’s informal caregivers are asked for
a blood sample.
Databases will be used to collect data about the patients
and caregivers use of healthcare (Table 2). All planned as-




Sample size was calculated considering the primary pur-
pose of this trial, which is to prolong patients’ residence at
home and to increase the number of patients who die at
home by 15 - 20%. The latter purpose serves as a proxy
for the first purpose. With a power of at least 80%, and an
effect difference of 15% at a significance level of 0.05, 170
patients are required in each study arm (Ficher´s exact
test). On the basis of this and an expected dropout rate of
10-15%, we plan to randomize 380 patients for the study.
Statistics analyses
Microsoft Access 2010® will be used as a database of infor-
mation on included patients. Data from the questionnaires
are scanned via ReadSoft Forms© (ReadSoft AB, Helsingborg,
Sweden) into another database. Before data analyses the
two databases will be merged.
The data analyses will comprise four main procedures:
1. Longitudinal analyses by multivariate linear mixed
effect regression model, in which changes over a
period of 2, 4 and 8 weeks will be compared. This
will include analysis of a) whether there is a
Table 2 Assessments in The DOMUS study
Investigators Patient Caregiver Bereaveda
Medical History • Cancer Diagnosis, Co-morbidity, Time of
Cancer Diagnosis, Current Disease Stage,




• Relationship Status, Children, Education Baseline Baseline
• Wishes for place of care and treatment Baseline Baseline
Week 2,4,8 Week 2,4,8
6 months 6 months





• Edmonton Symptom Assessment System









• Symptoms priority Baseline
Week 2,4,8
6 months
• Symptom Checklist-92, anxiety and
depression subscales (SCL-92) [37]
Baseline Baseline Week 2
Week 2,4,8 Week 2,4,8 2, 7, 13, 19 months
6 months 6 months
• Modified Medical Outcomes Study Social
Support Survey (mMOS-SS)b [38]
Baseline Baseline Week 2
2, 7, 13, 19 months
• Dyadic Coping Inventory (selected
subscales) (DCI)b [39]
Baseline Baseline
Week 2,4,8 Week 2,4,8
6 months 6 months
• Relationship ladderb [40] Baseline Baseline
Week 2,4,8
6 months
• Zarit Burden Interview (ZBI) [41] Baseline
Week 2,4,8
6 months
• Experiences in Close Relationships-Short
Form (ECR) [42]
Baseline 7, 13, 19 months
• Medical Outcomes Study Short Form
(SF-36) [43]
Baseline Week 2
Week 2,4,8 2, 7, 13, 19 months
6 months
• Inventory of Daily Widowed Life (IDWL) [44] Week 2
2, 7, 13, 19 months
• Pittsburgh Sleep Quality Index (PSQI) [45] Week 2
2, 7, 13, 19 months
• Prolonged Grief Disorder (PG – 13) [46] 7, 13, 19 months
• Lifestyle single items Week 2
2, 7, 13, 19 months
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Table 2 Assessments in The DOMUS study (Continued)
Blood samples • Telomere length Baseline 2 months




• Number of inpatient bed days
• Number of outpatient visits to hospitals
• Number of visits to GP
• Number of visits to the emergency room
• Number of visits to the emergency
physician
• Number of visits to specialists
• Treatments in public hospitals
• Prescribed drugs
• Place of care and death





a)The bereaved is the primary caregiver, b)Only patients with participating relatives, c)The National Patient Register, Health Insurance Registry, Medicine Databases.
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group during the follow-up, and b) if the changes
are similar for the two groups in between the
measurements at respectively 2, 4 and 8 - week
follow-up. In order to determine whether there is
a difference in survival between the two groups
Kaplan-Meier plot is used. Survival in the two
groups is also compared in a Cox regression,
which can be controlled for the same variables as
the analyses of questionnaire data.
2. Intention to treat analyses, in which changes in
outcome variables between the intervention and
control group of caregivers, will be tested by linear
“mixed-effect” regression models for repeated
measurements. These analyses will be conducted for
outcomes both before and after the patient’s death.
To investigate the possible effect modifications,
relevant interactions will be included, among these
interactions between the randomization group and
time since baseline, time since diagnosis, and
baseline values of outcomes.
3. Data collected in semi-structured interviews after
the intervention will be analyzed qualitatively to
identify how a selection of the bereaved caregivers
have experienced the care of the patient in their
homes and how they have experienced the intervention.
4. Cost-effectiveness analyses, in which multivariate
regression models will be used to analyze differences
in costs between the intervention- and control-group,
and to relate these to observed differences in effects.
5. Data collected in 10 – 12 focus groups will be
analyzed to describe the experiences of the
professionals involved in the trial; their evaluation of
cooperation and quality of treatment and care in the
patient trajectories.Trial plan
The trial is completed when the 340 patients have been
randomized and after the last patient has been followed
six months from baseline. Data collection is estimated to
go on for 2 years. However, the caregivers will continue
to be followed 19 months after the death of the patients.
Ethics
The National Committee on Health Research Ethics,
Denmark (37237) and The Danish Data Protection Agency
(2007-58-0015) have approved the DOMUS trial.
The DOMUS trial has the logical consequence that the
two groups of patients do not receive the same care. This
can be justified mainly by the lack of evidence of whether
accelerated transition from oncological treatment to SPC
at home as a whole has any effect on place of care and
death, symptoms/problems, quality of life, survival and
caregivers’ health and grief. Further, it should be empha-
sized that the patients in the control group will receive the
same treatment and care as they previously had, and as
others in similar circumstances. As already mentioned the
control group has the possibility of being referred to the
same treatment and care as the intervention group with
the exception of the psychological intervention. However,
the GPs can refer patients in the control group to psycho-
logical treatment outside of the trial. Finally, the study
staff will not prevent a potential crossover of patients.
Discussion
The DOMUS trial is a comprehensive RCT in incurable
cancer patients – to our knowledge the first of its kind - in-
cluding outcomes from the individual patient and closest
relative, as well as healthcare research of economy and
organization. The primary goal of this trial is to ensure
accelerated transition from hospital to SPC at home, so
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feral to and prolonged residence in their own homes
[11]. The model is based on already existing resources,
which are organized in a fixed sequence – a “fast-track
lane” - with the addition of a manualized psychological
intervention. The psychological intervention aims to
support patients and caregivers jointly, as coping with
severe illnesses depends, not only on the individual, but
the dyad [47]. The effect of accelerated transition to a
SPT enriched with a psychologist intervention will
hopefully provide further knowledge of the needs of pa-
tients and caregivers as well as the costs and the ex-
penses associated with the intervention. Finally, our
study will, due to the transparency (Ref: Clinicaltrials.
gov Identifier: NCT01885637) and the present paucity
of comprehensive RCTs regarding clinical, organizational
and health economical aspects of SPC, be valuable for
decision-making in our region as well as in countries
with comparable healthcare systems, and hopefully also
be a source of inspiration for other healthcare systems
[31,48]. In developing the DOMUS trial, the authors
have discussed several issues, which may raise criticism
and pose challenges to feasibility and influence outcomes.
One of them is obtaining agreement between patients and
relatives about place of care. In our population, we have
no data on the degree of agreement, which of course may
be highly dependent on the quality and extent of informa-
tion. In the DOMUS trial, this information is given by
trained research nurses and based on an information man-
ual regarding SPC at home. In a retrospective study, 80%
of the patients and relatives agreed on the preferred place
of death, and 20% of the relatives changed their minds
(in 51% of these cases the preference moved from home
to another setting) [49]. However, in this study the pa-
tients’ preferred place of death was given by the relatives
after the deaths of their loved ones, and therefore the
“true” proportion of agreement is uncertain [49]. Based
on the retrospective data and our clinical experience, we
anticipate that thorough and proper information about
SPC at home will create agreement in the majority of
cases.
Another issue of discussion in the DOMUS trial has
been to define the inclusion criteria. Cancer patients who
are eligible for SPT can be defined in many ways depend-
ing on the purpose of the study or clinical outcomes. A
RCT by Temel et al. demonstrated that patients with
newly diagnosed metastatic lung cancer benefitted from
referral to a SPT, as these patients achieved better quality
of life, were less depressed and lived longer than patients
in a control group who received standard therapy [48].
Thus, the Temel study was engaged in early intervention
of SPC for a specific cancer diagnosis [48], whereas our
study is engaged in defining patients with different cancer
diagnoses treated at a comprehensive cancer center inneed of SPC at home. Therefore, in addition to the
expressed wish (and agreement between patient and
closest relative) to be cared for at home, we have selected
the inclusion criteria “incurable cancer with limited or no
antineoplastic treatment left” (List of Inclusion and exclu-
sion criteria of the DOMUS study). Further, we have char-
acterized the meaning of “incurable cancer with limited or
no antineoplastic treatment left” for all involved diagnoses
(Table 1). Hence, we have sought to define a palliative pa-
tient population suitable for and in need of SPC at home,
which of course can be adapted to other diagnoses as well.
By defining limited treatment options, we have established
a set of criteria that are already an integrated part of onco-
logical treatment. With these criteria, we may in the fu-
ture enable clinicians to proactively identify patients in the
oncological treatment trajectory, who may benefit from
SPC. In the initial phase of the inclusion of patients ECOG
performance status 2–4 was an inclusion criterion. How-
ever, after a year of inclusion only 66 patients were en-
rolled. In order to speed up recruitment of patients as well
as attempting to study earlier SPC [29,48] we have decided
to remove the criteria (ECOG performance status 2–4).
Further, by deleting the inclusion criteria it will be possible
to investigate the difference effect of SPC in low and high
ECOG performance status patients. The changes will be
reported to clinicaltrial.gov.
The planned intervention is complex, including several
sequential elements, and therefore it will not be possible
to evaluate single elements of this multimodal trajectory
intervention. The accelerated transition from oncological
treatment requires a flexible primary care setting and a
SPT ready to take care of the patient at home within five
days of enrolment in the trial. The SPTs in the Capital
Region of Denmark have their own individual referral
guidelines and operate in less well-defined local areas.
To ensure an equal distribution of patients to the differ-
ent SPTs, the DOMUS protocol allocates patients to
relevant SPTs according to uniformed referral guidelines
and geographical based allocation. The geographical dis-
tribution of adequate SPC and the collaboration between
SPTs, GPs, and district nurses is a rather simple pre-
requisite for the delivery of good palliative care. In
addition, this issue may play a significant role even in
countries with well-developed palliative care. In the UK
with a comprehensive coverage of palliative care obtain-
able across the country, there seems to remain a lot of
inequity, including that relating to geography, diagnosis,
age and ethnicity [50]. In the DOMUS trial we will, in
addition to the introduction of uniformed referral guide-
lines and geographical based allocation, further investigate
these issues by adding qualitative interviews with patients,
informal caregivers and healthcare professionals.
Currently a psychological intervention is not included in
the standard SPT in Denmark, although it is recommended
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other medical professionals [14,51]. In five out of nine
SPTs in the Capital Region a psychologist is already part
of the hospice/palliative care unit team, but as the capacity
is limited the psychologists are only used for in-patients
except in two palliative care units, where they can par-
ticipate in SPC at home [32]. However, as all SPTs of
the region have agreed to participate in the DOMUS
trial, the standardized manualized psychologist inter-
vention is applied to all patients and relatives allocated
to the intervention group. Thus, if the multimodal tra-
jectory intervention enriched with a targeted psycholo-
gist intervention proves to be successful it may inspire
the future model for SPC.
The intervention proposed in the DOMUS trial requires
a consistent and intensified collaboration between health-
care professionals in the hospital, the primary healthcare
sector and the SPTs in order to give the patients the best
possible care at home. The DOMUS study is primarily im-
portant, because it can show whether the intervention can
improve the treatment of palliative patients and provide a
model for how the SPC should be organized in the com-
munity. It is essential to find out whether place of care
and death, longer survival and healthcare benefits are as-
sociated with the intervention. As the organizational and
financial consequences of the model will also be investi-
gated, there is a direct basis on which decisions can be
taken regarding the organization of future palliative care.
In addition to national importance of the study it has great
international relevance, since high quality evidence from
RCTs is sparse in palliative care, and no RCTs with an
accelerated transition from oncological treatment to
continuing SPC at home in patients with incurable cancer
have previously been published.
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